Published in Ann Clin Lab Sci on January 01, 2003
Carbon monoxide inhibits L-type Ca2+ channels via redox modulation of key cysteine residues by mitochondrial reactive oxygen species. J Biol Chem (2008) 1.12
Carbon monoxide improves cardiac function and mitochondrial population quality in a mouse model of metabolic syndrome. PLoS One (2012) 0.96
Emergent role of gasotransmitters in ischemia-reperfusion injury. Med Gas Res (2011) 0.89
Astaxanthin treatment confers protection against oxidative stress in U937 cells stimulated with lipopolysaccharide reducing O2- production. PLoS One (2014) 0.87
Biological functional relevance of asymmetric dimethylarginine (ADMA) in cardiovascular disease. Int J Mol Sci (2013) 0.86
Evaluation of the effectiveness of Piper cubeba extract in the amelioration of CCl4-induced liver injuries and oxidative damage in the rodent model. Biomed Res Int (2015) 0.81
Carbon monoxide affects electrical and contractile activity of rat myocardium. J Biomed Sci (2011) 0.77
Ion channels as effectors in carbon monoxide signaling. Commun Integr Biol (2009) 0.75
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J (2010) 16.39
Universal definition of myocardial infarction. Circulation (2007) 11.69
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace (2010) 6.31
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res (2004) 4.00
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Awake systolic blood pressure variability correlates with target-organ damage in hypertensive subjects. Hypertension (2007) 2.90
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation (2002) 2.18
Differential release of mast cell mediators and the pathogenesis of inflammation. Immunol Rev (2007) 1.94
Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol (2004) 1.79
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther (2006) 1.77
IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett (2003) 1.76
Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia-reperfusion injury in rat hearts. Cardiovasc Res (2005) 1.64
IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc Natl Acad Sci U S A (2010) 1.56
Complete myocardial revascularization: between myth and reality. Eur Heart J (2005) 1.55
Late thrombosis after double versus single drug-eluting stent in the treatment of coronary bifurcations: a meta-analysis of randomized and observational Studies. JACC Cardiovasc Interv (2013) 1.54
[Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation]. G Ital Cardiol (Rome) (2009) 1.52
Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci (2004) 1.50
Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics. J Clin Psychopharmacol (2005) 1.49
Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J (2005) 1.47
Impact of stress and mast cells on brain metastases. J Neuroimmunol (2008) 1.46
The adequacy of myocardial revascularization in patients with multivessel coronary artery disease. Int J Cardiol (2013) 1.45
Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am Heart J (2004) 1.41
Olive oil and red wine antioxidant polyphenols inhibit endothelial activation: antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler Thromb Vasc Biol (2003) 1.39
Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J (2004) 1.34
Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J (2011) 1.34
The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition. Proc Natl Acad Sci U S A (2006) 1.32
Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci (2006) 1.31
Recommendations for the management of patients after heart valve surgery. Eur Heart J (2005) 1.29
At least 2 distinct pathways generating reactive oxygen species mediate vascular cell adhesion molecule-1 induction by advanced glycation end products. Arterioscler Thromb Vasc Biol (2005) 1.27
Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch Biochem Biophys (2012) 1.24
Adipose tissue-derived stem cells: characterization and potential for cardiovascular repair. Arterioscler Thromb Vasc Biol (2009) 1.23
Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur Heart J (2011) 1.23
Basic mechanisms behind the effects of n-3 fatty acids on cardiovascular disease. Prostaglandins Leukot Essent Fatty Acids (2008) 1.22
Rapid decline of collateral circulation increases susceptibility to myocardial ischemia: the trade-off of successful percutaneous recanalization of chronic total occlusions. J Am Coll Cardiol (2006) 1.20
Cellular and molecular mechanisms of vascular injury in diabetes--part I: pathways of vascular disease in diabetes. Vascul Pharmacol (2011) 1.14
Brain cytokines and neuropsychiatric disorders. J Clin Psychopharmacol (2004) 1.14
Non-coronary atherosclerosis. Eur Heart J (2014) 1.11
Neoangiogenesis, T-lymphocyte infiltration, and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol (2004) 1.11
Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. J Clin Psychopharmacol (2007) 1.09
Spectrum of mast cell activation disorders. Expert Rev Clin Immunol (2014) 1.08
Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2 diabetes. Atherosclerosis (2009) 1.08
Advances in therapy with antileukotriene drugs. Ann Clin Lab Sci (2004) 1.07
Docosahexaenoic acid ethyl esters ineffective? Proc Natl Acad Sci U S A (2013) 1.07
Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. J Stroke Cerebrovasc Dis (2012) 1.05
A comprehensive outlook on intracerebral therapy of malignant gliomas. Crit Rev Oncol Hematol (2010) 1.04
Marine carotenoids and cardiovascular risk markers. Mar Drugs (2011) 1.03
Increased serum high-mobility group box-1 and cleaved receptor for advanced glycation endproducts levels and decreased endogenous secretory receptor for advanced glycation endproducts levels in diabetic and non-diabetic patients with heart failure. Eur J Heart Fail (2011) 1.03
Antiinflammatory effects in THP-1 cells treated with verbascoside. Phytother Res (2010) 1.02
Carotenoids and vitamins C and E in the prevention of cardiovascular disease. Int J Vitam Nutr Res (2012) 1.01
Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. Cardiovasc Res (2009) 1.01
Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci (2011) 1.01
Role of mast cells in tumor growth. Ann Clin Lab Sci (2007) 1.01
Adipose tissue: a new source for cardiovascular repair. J Cardiovasc Med (Hagerstown) (2010) 1.00
Homocysteine induces VCAM-1 gene expression through NF-kappaB and NAD(P)H oxidase activation: protective role of Mediterranean diet polyphenolic antioxidants. Am J Physiol Heart Circ Physiol (2007) 1.00
Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease. Vascul Pharmacol (2012) 1.00
Age-dependent impairment of number and angiogenic potential of adipose tissue-derived progenitor cells. Eur J Clin Invest (2010) 0.98
Novel phytonutrient contributors to antioxidant protection against cardiovascular disease. Nutrition (2012) 0.97
Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb Haemost (2014) 0.96
Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines. J Neuroimmunol (2004) 0.96
Bedside monitoring of antiplatelet therapy for coronary stenting. N Engl J Med (2013) 0.95
Contrasting effect of fish oil supplementation on the development of atherosclerosis in murine models. Atherosclerosis (2005) 0.94
Magnetocardiography: current status and perspectives. Part II: Clinical applications. Ital Heart J (2002) 0.94
Extremely low frequency electromagnetic field and wound healing: implication of cytokines as biological mediators. Eur Cytokine Netw (2013) 0.92
Novel therapeutic targets for autism. Trends Pharmacol Sci (2008) 0.92
Licocalchone-C extracted from Glycyrrhiza glabra inhibits lipopolysaccharide-interferon-γ inflammation by improving antioxidant conditions and regulating inducible nitric oxide synthase expression. Molecules (2011) 0.92
Activity of matrix metallo proteinases (MMPs) and the tissue inhibitor of MMP (TIMP)-1 in electromagnetic field-exposed THP-1 cells. J Cell Physiol (2012) 0.92
Left ventricular wall stress as a direct correlate of cardiomyocyte apoptosis in patients with severe dilated cardiomyopathy. Am Heart J (2003) 0.92
Hepatocyte growth factor/Met gene transfer in cardiac stem cells--potential for cardiac repair. Basic Res Cardiol (2010) 0.92
Quenching of intracellular ROS generation as a mechanism for oleate-induced reduction of endothelial activation and early atherogenesis. Thromb Haemost (2002) 0.91
Optical coherence tomography accurately identifies intermediate atherosclerotic lesions--an in vivo evaluation in the rabbit carotid artery. Atherosclerosis (2006) 0.91
Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guerin immunotherapy. Cancer Immunol Immunother (2002) 0.91
Energy metabolism in the normal and in the diabetic heart. Curr Pharm Des (2009) 0.91
Transplantation of mesenchymal cells rejuvenated by the overexpression of telomerase and myocardin promotes revascularization and tissue repair in a murine model of hindlimb ischemia. Circ Res (2013) 0.90
Phenotype modulation in cultures of vascular smooth muscle cells from diabetic rats: association with increased nitric oxide synthase expression and superoxide anion generation. J Cell Physiol (2003) 0.90
Association between plasma interleukin-18 levels and liver injury in chronic hepatitis C virus infection and non-alcoholic fatty liver disease. Ann Clin Lab Sci (2005) 0.90
[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol (2007) 0.90